Tempest Therapeutics, Inc. (TPST) is a Biotechnology company in the Healthcare sector, currently trading at $2.25. It has a SharesGrow Score of 51/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Valuation: TPST trades at a trailing Price-to-Earnings (P/E) of -0.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.03.
Net income is $26M (loss), growing at +4.3%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).
Balance sheet: total debt is $8M against $7M equity (Debt-to-Equity (D/E) ratio 1.22, moderate). Current ratio is 2.5 (strong liquidity). Debt-to-assets is 48.1%. Total assets: $17M.
Analyst outlook: 4 / 5 analysts rate TPST as buy (80%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 45/100 (Partial), Past 0/100 (Fail), Health 50/100 (Partial), Moat 28/100 (Fail), Future 90/100 (Pass), Income ?/100 (Fail).
